Clinical trials in Hildesheim

Extensive clinical trials focusing on various breast cancer subtypes, including HR-positive, HER2-positive, and triple-negative breast cancer. Studies evaluate new therapeutic approaches combining targeted therapies with standard treatments.

• Early-stage treatment optimization
• Novel drug combinations
• Personalized therapy approaches

Multiple trials investigating innovative treatments like ribociclib, elacestrant, and trastuzumab deruxtecan.

Groundbreaking research in hematologic malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, and Hodgkin lymphoma. Trials focus on improving treatment outcomes through targeted therapies.

• Novel treatment combinations
• Minimal residual disease monitoring
• Reduced toxicity approaches

Studies evaluate innovative drug combinations and personalized treatment durations.

Advanced research in colorectal cancer treatment, focusing on both colon and rectal cancers. Studies examine pre-operative treatments and novel therapeutic strategies.

• Pre-operative chemotherapy
• Organ preservation strategies
• Biomarker-guided therapy

Trials investigate customized treatment approaches based on disease staging and molecular markers.

Innovative trials in ovarian cancer treatment, exploring new therapeutic combinations and maintenance strategies. Research focuses on improving outcomes for newly diagnosed cases.

• Combination therapies
• Maintenance treatments
• Advanced disease management

Studies evaluate novel drug combinations including niraparib and bevacizumab.